Welcome to the Future of Specialty Pharmacy
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for GOMEKLI (mirdametinib). The Food & Drug Administration approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Being selected as a national pharmacy partner for GOMEKLI by SpringWorks Therapeutics, Inc. is a significant achievement for Onco360®. This partnership highlights the expertise and reputation that Onco360® has built over the years as the nation’s leading independent specialty pharmacy. GOMEKLI, also known as mirdametinib, has received approval from the Food & Drug Administration for the treatment of patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed surgically.
Neurofibromatosis type 1 is a genetic disorder that causes tumors to grow on nerves throughout the body. Plexiform neurofibromas are a common manifestation of NF1 and can cause pain, disfigurement, and other complications. The approval of GOMEKLI provides a new treatment option for patients with NF1 and PN, offering hope for improved outcomes and quality of life.
Onco360®’s role as a national pharmacy partner for GOMEKLI means that they will be responsible for providing this medication to patients across the country. This partnership speaks to the trust and confidence that SpringWorks Therapeutics, Inc. has in Onco360®’s ability to deliver high-quality specialty pharmacy services.
How This Will Affect Me:
As a patient with neurofibromatosis type 1 and symptomatic plexiform neurofibromas, the approval of GOMEKLI and Onco360®’s partnership with SpringWorks Therapeutics, Inc. mean that there is now a new treatment option available to me. This partnership ensures that I will have access to this medication through a trusted and reputable specialty pharmacy, giving me peace of mind and hope for improved health outcomes.
How This Will Affect the World:
The approval of GOMEKLI for the treatment of NF1 and PN represents a significant advancement in the field of rare disease treatment. This medication has the potential to improve the lives of patients with NF1 by providing a targeted therapy for their specific condition. Onco360®’s role as a national pharmacy partner for GOMEKLI demonstrates the importance of collaboration between pharmaceutical companies and specialty pharmacies in delivering innovative treatments to patients around the world.
Conclusion:
The partnership between Onco360® and SpringWorks Therapeutics, Inc. for the distribution of GOMEKLI marks a significant milestone in the treatment of neurofibromatosis type 1 and plexiform neurofibromas. This collaboration highlights the commitment of both companies to improving patient outcomes and advancing healthcare innovation. As we look to the future, partnerships like this will continue to shape the landscape of specialty pharmacy and rare disease treatment, ultimately benefiting patients and communities worldwide.
